Galecto to Highlight GB3226 Program at ASH 2025

Core Insights - Galecto, Inc. is presenting preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML), at the ASH Annual Meeting in December 2025 [1][2] Group 1: Product Overview - GB3226 is a first-in-class, orally bioavailable small-molecule inhibitor targeting ENL-YEATS and FLT3, which is mutated in approximately 30% of adult AML patients [2][4] - The dual inhibition of ENL-YEATS and FLT3 may provide greater therapeutic benefits compared to existing treatments [2] - Preclinical studies show GB3226's potent activity across diverse AML patient-derived samples, leading to rapid tumor regression and significantly prolonged survival in xenograft models [2][4] Group 2: Clinical Development - Two poster presentations will detail the Phase 1 study of GB3226 in patients with relapsed/refractory AML, scheduled for December 6 and December 8, 2025 [3] - The presentations will be held at the Orange County Convention Center in Orlando, Florida, during the ASH Annual Meeting [3] Group 3: Efficacy and Safety - GB3226 demonstrated favorable pharmacokinetics and tolerability in animal studies, with potential additive or synergistic effects when combined with current standard-of-care agents [2][5] - The investigational candidate showed superior efficacy compared to both FLT3 and menin inhibitors in preclinical models [4] Group 4: Company Background - Galecto is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and liver diseases, with a pipeline that includes GB3226 and other first-in-class small molecule drug candidates [6]